# A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

> **NCT04631016** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 137 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Bronchitis

## Interventions

- **DRUG:** Tozorakimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04631016
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-11-13
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04631016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04631016, "A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04631016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*